WT
MYGN icon

Washington Trust’s Myriad Genetics MYGN Stock Holding History

Washington Trust’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-165
Closed -$1.46K – 547
2025
Q1 		$1.46K Buy
165
+9
+6% +$108 ﹤0.01% 733
2024
Q4 		$2.14K Sell
156
-13
-8% -$240 ﹤0.01% 802
2024
Q3 		$4.63K Buy
169
+11
+7% +$298 ﹤0.01% 746
2024
Q2 		$3.87K Sell
158
-3
-2% -$66 ﹤0.01% 768
2024
Q1 		$3.43K Sell
161
-3
-2% -$64 ﹤0.01% 777
2023
Q4 		$3.14K Buy
+164
New +$2.84K ﹤0.01% 767

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Washington Trust's MYGN Position: Q2 2025 in Review

Washington Trust sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 165 shares — an estimated $1.46K sold.

Washington Trust first reported a position in MYGN in Q4 2023 and held it in 6 quarters. The position peaked at $4.63K in Q3 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.

  • Washington Trust reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
  • Washington Trust sold 165 Myriad Genetics shares in Q2 2025, an estimated $1.46K.
  • Washington Trust first reported a position in Myriad Genetics in Q4 2023 and held it in 6 quarters.
  • Washington Trust's Myriad Genetics position peaked at $4.63K in Q3 2024.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.

Based on Washington Trust's 13F filing for Q2 2025, filed 8 Aug 2025.